Ponentes

Alejandro Arenas-Pinto MBBS, MSc, PhD
Alejandro Arenas-Pinto MBBS, MSc, PhD
Alejandro Arenas-Pinto is a Venezuelan physician with training in infectious diseases and Tropical Medicine. Initially trained at Universidad Central de Venezuela, then completed his MSc in Infectious and Health in the Tropics at the London School of Hygiene and Tropical Medicine (Distinction) and obtained the Diploma in Tropical Medicine and Hygiene from the Royal College of Physicians. He gained his PhD from University College London (UCL) in 2006 on HIV and AIDS. Since 2004, Alejandro has been working at the UCL Centre for Clinical Research in Infection and Sexual Health, which is attached to one of the largest HIV clinics in the UK. Alejandro joined the Medical Research Council (MRC) Clinical Trials Unit at UCL as Senior Clinical Scientist in 2008 and has been working on national and international clinical trials on treatment of HIV disease ever since.
Gabriele Arendt, MD.
Gabriele Arendt, MD.

Gabriele Arendt, MD, is associate Professor in Neurology, University Hospital of Duesseldorf, Germany. Since 1987, she chairs the Neuro-AIDS out-patient department of the hospital with about 1100 patients/year. The Duesseldorf HIV cohort comprises by now almost 5000 patients. She acquired her medical and scientific degrees in the University of Duesseldorf, then specialised on psychiatry and later on neurology and neurophysiology. Her scientific interest focuses on motor abnormalities in HIV-positive patients, disturbances of the dopaminergic pathways in these patients and on the significance of cytokines for the neuropathogenesis of HIV-associated dementia.

She is in the editorial boards of the Journal of NeuroVirology, the Journal of NeuroAIDS and of Neurobehavioral HIV Medicine, an open access journal. She is a member of the German Aids Society. She has written more than 150 papers, HIV/AIDS chapters in most of the German standard textbooks and three books. She has designed and conducted many national multicenter studies and participated in international studies.

Andrea Calcagno, MD, DTM&H.
Andrea Calcagno, MD, DTM&H.

He is temporary Assistant Professor at the University of Torino (Department of Medical Sciences, Infectious Diseases). Infectious Diseases Specialist (University of Torino, Italy); Diploma in Tropical Medicine and Hygiene (Mahidol University, Bangkok, Thailand). He is member of the Panel of the Italian Guidelines on the Use of Antiretrovirals and Management of patients living with HIV.

He has experience as a Clinicians in Infectious Diseases and Tropical Medicine (Sudan, Thailand, Burundi); several phase II, III and IV studies in antiretroviral treatment trials.

His main field of interest is the clinical pharmacology and pharmacogenetics of anti-infective agents (antiretroviral, antibiotic, antifungals) and the central nervous system complication of HIV-infection.

Paola Cinque, MD, Ph. D.
Paola Cinque, MD, Ph. D.

She is currently working as senior physician at the Department of Infectious Diseases and responsible of the Neurovirology Research Unit at the Research Division of Immunology, Transplantation and Infectious Diseases of San Raffaele Scientific Institute, Milan, Italy, and as contract Professor of Infectious Diseases at San Raffaele University.

Her research group is mainly involved in studies on HIV Infection of the Central Nervous System, Progressive Multifocal Leukoencephalopathy and other HIV-associated CNS complications.

She is a panel member of the Italian HIV Treatment Guidelines, of the EACS Co-morbidities and of the Opportunistic Infections Guidelines, and of the NIH/CDC/IDSA Guidelines for the Prevention and Treatment of Opportunistic Infections.in HIV-Infected Adults and Adolescents.

Guida da Ponte, Ph. D.
Guida da Ponte, Ph. D.

Guida da Ponte is a Psychiatry Consultant, Coordinator of Liaison Psychiatry Unit, in Centro Hospitalar Barreiro-Montijo, located in the suburban area of Lisbon, Portugal. One of the major fields of practice is with HIV patients with a psychiatric outpatient clinic dedicated to this condition. Author of scientific publications, mainly in the areas of neurocognitive disorders, depression, anxiety and psychopharmacology and antiretroviral interactions. Other major area of interest is Psycho-Oncology, as PhD student of Medical School of Lisbon, University of Lisbon.

David Grelotti, MD
David Grelotti, MD
Dr. Grelotti is an Assistant Professor of Psychiatry at the University of California San Diego and an Investigator at the University of California Center for Medicinal Cannabis Research. An adult and child psychiatrist, he graduated from medical school at the Johns Hopkins University School of Medicine and completed residency training in the Harvard Medical School Combined Pediatrics, Adult Psychiatry, and Child Psychiatry Residency Training Program at Massachusetts General Hospital and McLean Hospital. At UC San Diego, he directs psychiatric service provision for patients with HIV and conducts research on HIV syndemics, global mental health, and medicinal cannabis. Active research efforts include novel systems for the delivery of mental health treatment for people living with HIV in Haiti and the US; recreational antiretroviral use in South Africa; and cannabis-related driving impairment and a randomized, placebo-controlled clinical trial of cannabis for low back pain. His research is funded by the National Institutes of Health and the State of California.
Scott Letendre, MD.
Scott Letendre, MD.

Scott Letendre, M.D., is Professor of Medicine in Residence in the Division of Infectious Diseases at the University of California, San Diego (UCSD). He graduated from Georgetown University School of Medicine and, following his residency in internal medicine at the Naval Medical Center in San Diego, he completed fellowships in Infectious Disease Medicine at Duke University and in Neurologic HIV Research at UCSD. At UCSD, Dr. Letendre performs translational, patient-oriented research of the central nervous system complications of chronic infections, including HIV, HCV, and CMV. As part of a multidisciplinary research team, he conducts treatment trials of neurocognitively impaired individuals and analyzes their response to therapy as well as studies of the pharmacokinetics of antiretrovirals, the effect of comorbidities, and biomarker correlates of disease. Dr. Letendre is also an investigator in the UCSD unit of the AIDS Clinical Trials Group.

He participates in several international research projects, including projects based in China, India, Zambia, and Romania. Dr. Letendre balances his research activities with regular, clinical outpatient and inpatient care of people living with HIV and other infectious diseases. Dr. Letendre also teaches in the Microbiology course at the UCSD School of Medicine and chairs the UCSD Institutional Biosafety Committee. Dr. Letendre has published in several peer-reviewed journals including AIDS, Clinical Infectious Diseases, Journal of Infectious Diseases, Neurology, Journal of Virology, Journal of Neurovirology, Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, and Journal of Neuroimmunology.

Catia Marzolini, PharmD PhD
Catia Marzolini, PharmD PhD

Dr Catia Marzolini obtained a degree in Pharmacy followed by a PhD in Clinical Pharmacology at the University of Lausanne, Switzerland. She completed a post-doctoral fellowship in the pharmacogenetics of drug transporters within the Division of Clinical Pharmacology at Vanderbilt University, Nashville, USA. She obtained subsequently the “venia docenti” from the University of Basel.

Catia Marzolini is currently working as a senior research scientist in the Division of Infectious Diseases & Hospital Epidemiology at the University Hospital of Basel. Her research focuses on pharmacological and genetic determinants of antiretroviral drug response and toxicity. Catia Marzolini has become an expert in the field of HIV drug-drug interactions. She is a member of the Liverpool HIV drug-drug interactions website and is notably in charge of predicting drug-drug interactions. Catia Marzolini has also joined the European AIDS Clinical Society (EACS) guidelines committee panel for the pharmacological aspects of HIV therapy.

Jose A. Muñoz-Moreno, Ph. D.
Jose A. Muñoz-Moreno, Ph. D.

Jose A. Muñoz-Moreno is a clinician and researcher at the Lluita contra la SIDA Foundation, located in the Germans Trias i Pujol University Hospital, in Barcelona (Catalonia, Spain). He earned the Ph.D. degree in Neurosciences in 2012 (Cum Laude), and currently he is also a collaborating professor with the Universitat de Barcelona (UB) and the Universitat Autònoma de Barcelona (UAB).

Muñoz-Moreno is involved in projects that address psychology and the human behaviour associated with HIV infection. In terms of study, he mostly investigates the neurocognitive features of HIV infection, the impact of HIV and antiretroviral treatments on quality of life and emotional status, and adherence to antiretroviral therapy.

Muñoz-Moreno’s recent work particularly focuses on assessment methods to detect HIV-related neurocognitive changes and the current profile of neurocognitive impairment in people living with HIV infection.

Ignacio Pérez-Valero, MD, Ph. D.
Ignacio Pérez-Valero, MD, Ph. D.
Ignacio Pérez-Valero MD PhD is a 41 years-old Consultant Physician of Internal Medicine at the La Paz University Hospital and a Senior Clinical Researcher at the IDIPAZ Research Institute (Madrid, Spain).
Amnemiek Shadé, MD, PhD
Amnemiek Shadé, MD, PhD

Annemiek Schadé works as a psychiatrist since2005 at the HIV Expert and Treatment Center on HIV and Mental Health and as a consultant at the University Hospital VU Medical Center in Amsterdam. She is a trainer for medical residents psychiatry and interns. The past years, she provided trainings on HIV and Mental Health in former Soviet Republics and new EU-countries. She published a study book and (research) articles on HIV and Mental Health.

Milton Wainberg, MD
Milton Wainberg, MD
Milton Wainberg is Professor of Clinical Psychiatry and Director of Global Mental Health Research in the Department of Psychiatry, Columbia University. He is Director of the NIMH-funded Columbia University Global Mental Health Implementation Science T32-Post Doctoral Fellowship, NIMH/Fogarty International-funded Portuguese-speaking African countries Mental Health Implementation Research Training Program, Founding Chair of the Caucus of Global Mental Health and Psychiatry of the American Psychiatric Association, and Medical Director of the Columbia University HIV Mental Health Training Project. Dr. Wainberg is the Chair of the Mental Health HIV Clinical Guidelines Committee of the New York State Department of Health/AIDS Institute, and has been Principal investigator or investigator of multiple NIMH, NIAAA, NIDA and CDC studies addressing the intersection of mental illness, substance use and abuse, HIV-associated fatigue, sexual compulsivity and HIV prevention and adherence to care, as well as the stigma and discrimination associated with mental illness, HIV, race/ethnicity and being a sexual minority. Dr. Wainberg is the Principal Investigators of the NIMH-funded PRIDE sSA - Partnerships in Research to Implement and Disseminate Sustainable and Scalable Evidence-based Practices: sub-Saharan Africa which comprises a large scale up study delivering comprehensive efficacious and sustainable psychiatric care in three Provinces of Mozambique, and capacity building of a collaborative research network that will train service providers, investigators and policy-makers from Botswana, Malawi, Mozambique, South Africa, Zambia.  His research to practice work aims to decrease the global mental health treatment and research gaps.
Alan Winston, MD.
Alan Winston, MD.
Dr.Winston is a Clinical Senior Lecturer in Communicable Diseases at Imperial College, London and Consultant Physician in HIV and GU Medicine at St. Mary’s Hospital, London. Dr.Winston is a clinical researcher with an MD in clinical pharmacology and runs a portfolio of clinical trials assessing non-infectious co-morbidities, including cerebral function, in relation to HIV disease with a focus on antiretroviral pharmacokinetics and pharmacodynamics in sanctuary sites.

Ver el programa